Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TemAvIr: Bevacizumab/Irinotecan vs Stupp in Glioblastoma
NCT01022918Phase 2Completed
- Sponsor
- Centre Georges-François Leclerc
- Start
- Jan 2009
- Primary completion
- Jul 2010
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab, irinotecan in glioblastoma (GBM), sponsored by Centre Georges-François Leclerc. Started Jan 2009; status: completed.
02
Drugs
bevacizumabirinotecan
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT01022918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01022918.